Skip to content

Clinical observation on curative effect of uniting use of Capsules of compound Cortex Moutan & Leech and Aspirin on improving the prethrombotic state in patients with Type 2 diabetes mellitus and hypertension

Clinical observation on curative effect of uniting use of Capsules of compound Cortex Moutan & Leech and Aspirin on improving the prethrombotic state in patients with Type 2 diabetes mellitus and hypertension

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-12002780
Enrollment
Unknown
Registered
2012-08-27
Start date
2012-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus AND Cardiovascular disease

Interventions

Group A (hypertension group):Add a Dan vermiculite hypoglycemic capsule
Group B (hypertension combined type 2 diabetes gro :Add a Dan vermiculite hypoglycemic capsule

Sponsors

Senium Vasculocardiology Deparment, The first affiliated hospital of TCM college of Anhui province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
51 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Regular oral aspirin > 100mg, qd >2 weeks routinely in hypertension patients; 2. Regular oral aspirin > 100mg, qd >2 weeks routinely in patients with hypertension or hypertension combined with type 2 diabetes.

Exclusion criteria

Exclusion criteria: 1) lack of age fifty years or more than 100 years old; 2) pregnancy or lactation women; 3) the existence of anticoagulant therapy contraindications; 4) always did large surgery; 5) cancer or other diseases reduce the expected life; 6) not control infection or sepsis; 7) cardiopulmonary liver and kidney and other organs serious diseases; 8) at the same time to accept other anticoagulation and antiplatelet drugs, nonsteroidal anti-inflammatory drugs and so on influence of platelet function drugs.

Design outcomes

Primary

MeasureTime frame
Clotting;Platelet aggregation function;CD61, CD40, CD3;

Countries

China

Contacts

Public ContactHaiqin Tang
tanghq898@sina.com+86 13905696689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026